期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

三阴性乳腺癌96例临床特征与预后分析 被引量：10

原文传递
导出
摘要 目的 分析三阴性乳腺癌（TNBC）患者临床特征和影响预后的因素.方法 经病理组织学确诊、有完整随访资料的可手术乳腺癌患者96例,经病理学检查证实雌激素受体（ER）、孕激素受体（PR）和Her-2/neu均为阴性,回顾性分析患者的临床特征、复发及生存情况.结果 TNBC患者中位随访时间为43个月（24～81个月）,有71例患者出现复发及转移,28例死亡.单因素分析发现肿瘤大小、淋巴结状况、是否化疗均可影响患者的生存时间.多因素分析提示肿瘤大小、是否化疗是影响TNBC预后的主要因素.结论 TNBC是一种独立的临床病理类型,以侵袭性强、预后较差为主要特征的乳腺癌应争取早诊断、早治疗.
作者 王传省 张芳
机构地区 山东省淄博市第一医院肿瘤科
出处 《肿瘤研究与临床》 CAS 2013年第5期350-352,共3页 Cancer Research and Clinic
关键词 乳腺肿瘤 雌激素受体 孕激素受体 人类表皮生长因子受体 预后
分类号 R737 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1Anders CK, Carey LA. Biology,metastatic patterns, and treatment ofpatients with triple-negative breast cancer. Clin Breast Cancer, 2009,9: s73-s81.
  • 2Carey LA, Perou CM, Livasy CA, et al. Race,breast cancer subtypes,and survival in the Carolina Breast Cancer Study. JAMA,2006, 295:2492-2502.
  • 3Korsching E, Jeffrey SS, Meinerz W, et al. Basal carcinoma of thebreast revisited: an old entity with new interpretations. J Clin Pathol,2008,61: 553-560.
  • 4Stead L, Lash T, Sobieraj J, et al. Triple - negative breast cancers areincreased in black women regardless of age or body mass index. BreastCancer Res, 2009, 11: 18.
  • 5Lund M, Trivers K, Porter P, et al. Rare and triple negative threats tobreast cancer survival: a population-based study in Atlanta,GA. BreastCancer Res Treat, 2009, 113: 357-370.
  • 6Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers intriple-negative breast cancer. Cancer, 2007, 109: 25-32.
  • 7Osbourne CR, Kannan L, Ashfaq R, et al. Clinical and pathologicalcharacterization of basal - like breast cancer. Breast Cancer Res Treat,2005,94: si 18.
  • 8Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al. Prognostic significance. of basal-like phenotype and fascin expression in nodenegativeinvasive breast carcinomas. Clin Cancer Res, 2006,12: 1533-1539.
  • 9袁中玉,王树森,高岩,苏争艳,罗文标,管忠震.305例三阴乳腺癌患者的临床特征及预后因素分析[J].癌症,2008,27(6):561-565. 被引量：161
  • 10Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox:primary tumor chemosensitivity of breast cancer subtypes. Clin CanrerRes, 2007, 13:2329-2334.

二级参考文献53

  • 1Perou CM, Srlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature, 2000, 406: 747-752.
  • 2Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 2004, 10: 5367-5374.
  • 3Rakha EA, E1-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer.Cancer, 2007, 109: 25-32.
  • 4Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer, 2007, 109: 1721-1728.
  • 5Dent R, Trudean M, Pritchard KI, et al. Triple-negative breast cancer:. clinical features and patterns of recurrence. Clin Cancer Res, 2007, 13: 4429-4434.
  • 6Kim M J, Ro JY, Ahn SH, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her-2/neu- overexpressing phenotypes. Hum Pathol, 2006, 37: 1217-1226.
  • 7Sara M, Bando Y, Takahashi M, et al. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple- negative breast cancer. J Surg Oncol, 2008, 97: 30-34.
  • 8Rodenhuis S, Bontenbal M, van Hoesel QG, et al. Efficacy of high- dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol, 2006, 17: 588-596.
  • 9Torrisi R, Balduzzi A, Ghisini R, et al. Tailored preoperative treatment of locally advanced triple negative ( hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel., Cancer Chemother Pharmacol, 2005, 62: 667-672.
  • 10Leator S, Heller W, Coombes RC. Triple-negative breast cancer:. therapeutic options. Lancet Oncol, 2007, 8: 235-244.

共引文献174

同被引文献93

  • 1国家中医药管理局.中医病证诊断疗效标准[S].南京:南京大学出版社,1997.197.
  • 2Lin PH,Lu YS.Vinorelbine plus 24-hour infusion of high-dose 5-fluorouracil and leucovorin as effective palliative chemotherapy for breast cancer patients with acute disseminated intravascular coagulation[J].Anticancer Res,2010,30(7):3087-3091.
  • 3邵志敏,沈镇宙,徐兵河,主编.乳腺肿瘤学[M].上海:复旦大学出版社,2013: 24-25.
  • 4Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma[J]. Mod Pathol, 2006, 19: 264-271.
  • 5Noruzinia M, Coupier I, Pujol P. Is BRCAI/BRCA2 related breast carcinogenesis estrogen dependent?[J]. Cancer, 2005, 104: 1567- 1574.
  • 6Zakhartseva LM, Gorovenko NG, Podolskaya SV, et al. Breast cancer immunohistochemical features in young women with BRCA 1/2 mutations[J]. Exp Oncol, 2009, 31: 174-178.
  • 7Kwong A, Wong LP, Wong HN, et al. Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer[J]. Hugo J, 2009, 3: 63-76.
  • 8Yip CH, Taib NA, Choo WY, et al. Clinical and pathologic differences between BRCA1-, BRCA2-, and Non-BRCA-associated breast cancers in a multiracial developing country[J]. World J Surg, 2009, 33: 2077- 2081.
  • 9Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer[J]. J Clin Oncol, 2008, 26: 4282-4288.
  • 10Armes JE, Trute L, White D, et al. Distinct Molecular Pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers a population-based study[J]. Cancer Res, 1999, 59:2011-2017.

引证文献10

二级引证文献49

肿瘤研究与临床
2013年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部